Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Kaitlin J Mayne,Rebecca J Sardell,Natalie Staplin,Parminder K Judge,Doreen Zhu,Emily Sammons,David Z I Cherney,Jennifer B Green,Adeera Levin,Roberto Pontremoli,Sibylle J Hauske,Jonathan Emberson,David Preiss,Martin J Landray,Colin Baigent,Christoph Wanner,Richard Haynes,William G Herrington,EMPA-KIDNEY Collaborative Group,Martina Brueckmann,Mark Hopley,Maximillian von-Eynatten,Jyothis George,Alfred K Cheung,Zhi-Hong Liu,Jing Li,Laiseong Hooi,Wen Liu,Takashi Kadowaki,Masaomi Nangaku,David Cherney,Aldo P Maggioni,Stefan Hantel,Shinya Goto,Rajat Deo,Katherine R Tuttle,Parminder Judge,Sarah Y A Ng,Xavier Rossello,Peter Sandercock,Rudolf Bilous,Charles Herzog,Paul Whelton,Janet Wittes,Derrick Bennett
DOI: https://doi.org/10.1093/ndt/gfae203
2024-09-14
Abstract:Background and hypothesis: Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD. Methods: The EMPA-KIDNEY trial randomised 6609 patients with CKD (estimated glomerular filtration rate [eGFR] ≥20 and <90 mL/min/1.73m2) to receive either empagliflozin 10 mg daily or matching placebo over a median of two years follow-up. Serum uric acid was measured at randomisation then 2 and 18 months of follow-up and the effects of empagliflozin were analysed using a pre-specified mixed model repeated measures approach. Participant-reported gout events were analysed in Cox regression models (first events) with the Andersen-Gill extension (total events). A post-hoc composite outcome included new initiation of uric acid lowering therapy or colchicine. EMPA-KIDNEY primary and kidney disease progression outcomes were also assessed in subgroups of baseline serum uric acid. Results: Baseline mean ± SD serum uric acid concentration was 431±114 µmol/L. Allocation to empagliflozin resulted in a study-average between-group difference in serum uric acid of -25.6 (95%CI -30.3,-21.0) µmol/L with larger effects in those with higher eGFR (trend P < 0.001) and without diabetes (heterogeneity P < 0.001). Compared to placebo, empagliflozin did not significantly reduce first or total gout events (HR 0.87, 95%CI 0.74-1.02 for the 595 first events, and 0.86, 0.72-1.03 for the 869 total events) with similar hazard ratios for the post-hoc composite and across subgroups, including by diabetes and eGFR. The effect of empagliflozin on the primary outcome and kidney disease progression outcomes were similar irrespective of baseline level of uric acid. Conclusion: SGLT2 inhibition reduces serum uric acid in patients with CKD with larger effects at higher eGFR and in the absence of diabetes. However, the effect on uric acid is modest and did not translate into reduced risk of gout in EMPA-KIDNEY.